CONMED Corporation (CNMD)

Return on equity (ROE)

		Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net income	US$ in thousands	132,423	64,459	-80,582	62,542	9,517
Total stockholders’ equity	US$ in thousands	962,681	834,222	745,545	785,435	709,038
ROE		13.76%	7.73%	-10.81%	7.96%	1.34%

December 31, 2024 calculation

ROE = Net income ÷ Total stockholders’ equity
= $132,423K ÷ $962,681K
= 13.76%

Based on the data provided, CONMED Corporation's return on equity (ROE) has shown significant fluctuations over the past five years.

In 2020, the ROE was a modest 1.34%, indicating a relatively low return generated on shareholders' equity. However, by the end of 2021, the ROE had improved to 7.96%, suggesting a better utilization of equity to generate profits.

The following year, in 2022, the ROE took a negative turn, standing at -10.81%. This indicates that the company's net income was insufficient to cover the equity invested, resulting in a negative return for shareholders.

Nevertheless, CONMED Corporation managed to bounce back in 2023 with an ROE of 7.73%, showing a recovery from the previous year's negative performance.

By the end of 2024, the ROE experienced a notable increase to 13.76%, demonstrating a significant improvement in profitability and efficiency in utilizing equity to generate returns for shareholders.

Overall, the fluctuating trend in CONMED Corporation's ROE over the past five years suggests variability in the company's profitability and the effectiveness of utilizing shareholders' equity. It would be important to further analyze the factors driving these fluctuations to assess the company's financial performance and sustainability.